Moreover, other treatment strategies against MCC and other skin cancers are currently under investigation, including PI3K/mTOR inhibitors, domatinostat, adoptive cell therapy, and next-generation immune checkpoint inhibitors, such as anti-TIM-3, anti-TIGIT, and anti-LAD-3. This evidence concerns the gene MTOR and skin cancer.